Press Release Details

Revance Therapeutics to Present at Credit Suisse 24th Annual Healthcare Conference

November 04, 2015

NEWARK, Calif., Nov. 4, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that its management is scheduled to participate in the Credit Suisse 24th Annual Healthcare Conference in Phoenix, AZ.

Revance management is scheduled to present on Tuesday, November 10, 2015 at 7:30am MST (9:30am EST). Interested parties can access the live audio webcast for this conference presentation at http://investors.revance.com/index.cfm. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days.

About Revance Therapeutics, Inc.

Revance is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. The company is leveraging its proprietary portfolio of botulinum toxin compounds combined with its patented TransMTS® peptide delivery system to address unmet needs in the large and growing neurotoxin markets. Revance's proprietary TransMTS technology enables delivery of botulinum toxin A through two novel drug product candidates, a needle-free topical form and an injectable form that may localize the drug to the site of injection resulting in a targeted and potentially long-lasting delivery. Revance is pursuing clinical development for drug product candidates RT001 topical and RT002 injectable in a broad spectrum of aesthetic and therapeutic indications. The company holds worldwide rights for all indications of RT001, RT002 and the TransMTS technology platform. More information on Revance Therapeutics can be found at www.revance.com.

"Revance Therapeutics", TransMTS® and the Revance logo are registered trademarks of Revance Therapeutics, Inc.

CONTACT: Investors:

         Revance TherapeuticsJeanie Herbert

         (714) 325-3584

         jherbert@revance.com



         Westwicke PartnersLeigh Salvo

         (415) 513-1281

         leigh.salvo@westwicke.com



         Trade Media:

         Nadine Tosk

         (504) 453-8344

         nadinepr@gmail.com
Source: Revance Therapeutics, Inc.

News Provided by Acquire Media

image description